Rob Arnold is a Healthcare Innovation Advisor at the University of Washington and Partner at Quad+Aim Partners advising emerging growth companies on business strategy, planning, and investment. Prior to UW, Rob was CEO of Geospiza, Inc., a leader in cloud computing solutions for genetic analysis, which was sold to Perkin Elmer in May of 2011. Prior to Geospiza, Rob was CEO of Crossport Systems, a leader in internet security solutions, which was sold to Lineo/Metrowerks, a division of Motorola. Rob also co-founded and was CEO of ST Labs, Inc., an international leader in software quality assurance and testing, which was sold to Lionbridge.

Stephen Runnels has more than twenty-eight years of successful and proven international business management experience in the healthcare industry. He has held the position of President and CEO of several startup biopharmaceutical companies in the US and internationally. He was executive vice president and board member of publicly traded NeoTherapeutics, Inc. and vice president of marketing and business development at Sigma-Aldrich, a fortune 500 company. 

He has led drug discovery and in vitro diagnostic product development activities in the therapeutic areas of the central nervous system, oncology, clinical cytogenetics, assisted reproductive technologies, immunohematology and disease of bone and cartilage.

Mr. Runnels is an entrepreneur in residence at the University of Washington and recently held the position as CEO of ProtoTech, Inc., a private, clinical stage company focused on the development of therapeutics for Parkinson's disease, Alzheimer's disease, and AL Amyloidosis. He is a senior industry advisor for the National Institutes of Health Commercialization Program, managed by the Los Angeles Regional Technology Association. He was on the advisory board for extension courses in medical product development at the University of California - Irvine and is on the board of directors at Biosome, Inc. Mr. Runnels holds a B.S. in Cell Biology and a certification from the American Society of Clinical Pathology as a specialist in Immunhematology. He is an M.B.A. and Ph.D. candidate in management.

Richard Rylander, Jr. has more than 40 years experience in pharmaceutical and biotech, covering a wide range of areas including sales, management, marketing, training, operations, market research, and IT. His ground-breaking work creating the specialty distributions systems for Tracleer® and Zavesca® became the basis for the FDA's Risk Evaluation and Mitigation Strategies program. He is also an inventor and patent holder. His device development work in diabetes combined several technologies for a unique product.

Having launched several Orphan drugs, Rylander is well versed in identifying unique market niches as well as dealing with managed care, pricing, reimbursement, Medicare and Medicaid. He has also created call center support systems, including a unique software system for managing high-risk patients. Rylander has been involved in multiple startups and has consulted for companies evaluating new products. He has extensive experience in contract negotiation and management, performance review systems, and incentive planning.